Miromatrix Medical Inc

Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. It offers perfusion decellularization and recellularization technology, as well as organ-derived biological products such as MIROMESH and MIRODERM for soft tissue reinforcement and advanced wound care. The company was founded in 2009 by Doris A. Taylor and Cohen Robert and is headquartered in Eden Prairie, MN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Miromatrix Medical is a biotechnology company engaged in the development of fully biological human organs and organ-derived biological products to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization or recellularization technology, as well as organ-derived biological products for applications such as soft tissue reinforcement and advanced wound care.  It was founded in 2009 and is based in Eden Prairie, Minnesota.

EDEN PRAIRIE, Minn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2022 financial results and provided a corporate update.

Miromatrix Reports Second Quarter 2022 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced today that it has appointed Jack Lake, M.D. as the Company's new Medical Director.

Miromatrix Appoints Jack Lake, M.D., as Medical Director

EDEN PRAIRIE, Minn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Miromatrix to Report Second Quarter 2022 Financial Results

EDEN PRAIRIE, Minn., July 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, applauds the U.S. Food and Drug Administration (FDA) for hosting a two-day public advisory committee meeting to discuss scientific and regulatory topics relating to the field of organ transplant, specifically xenotransplantation. Opening remarks from the FDA highlighted the limited availability of human organs for transplant and recognized the tremendous unmet need for new treatments for patients with end-stage organ failure.

Miromatrix Applauds the FDA for Its Continued Commitment to the Field of Organ Transplant

EDEN PRAIRIE, Minn., May 31, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the upcoming 2022 American Transplant Congress held on June 4th to June 8th, 2022.

Miromatrix Announces Participation in the 2022 American Transplant Congress

EDEN PRAIRIE, Minn., May 25, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that members of the management team will participate in the upcoming 19th Annual Craig-Hallum Institutional Investor Conference on June 1st, 2022. Due to the format of this event, no webcast will be available.

Miromatrix Announces Participation in the 19th Annual Craig-Hallum Institutional Investor Conference

Miromatrix Medical Inc. (NASDAQ:MIRO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Hannah Jeffrey - Gilmartin Group LLC Jeff Ross - CEO Jim Douglas - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Operator Greetings and welcome to Miromatrix Medical Inc.'s First Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.

Miromatrix Medical Inc. (MIRO) CEO Jeff Ross on Q1 2022 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn., May 16, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported first quarter 2022 financial results and provided a corporate update.

Miromatrix Reports First Quarter 2022 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., April 28, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the first quarter 2022 after market close on Monday, May 16, 2022. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Miromatrix to Report First Quarter 2022 Financial Results

EDEN PRAIRIE, Minn., April 19, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that CEO Jeff Ross will present at the 2022 Cell & Gene Meeting on the Mediterranean. The conference, held this year on April 20 – 22 in Barcelona, Spain, brings together the leading public and private sector companies in the field of advanced therapies.

Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Med

Miromatrix Medical Inc. (MIRO) CEO Jeff Ross on Q4 2022 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn., March 30, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported fourth quarter and full year 2021 financial results and provided a corporate update.

Miromatrix Reports Fourth Quarter and Full Year 2021 Results and Provides Corporate Update

Allego NV

Alpha Tau Medical

Forge Global Holdings Inc

Leafly Holdings

JX Luxventure Ltd

NeuroSense Therapeutics Ltd

Kidpik Corp

Society Pass

SciSparc Ltd

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and bring order to the markets.

12 Stocks Halted On A Circuit Breaker This Week

EDEN PRAIRIE, Minn., March 17, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, March 30, 2022. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Miromatrix to Report Fourth Quarter and Full Year 2021 Financial Results

EDEN PRAIRIE, Minn., March 16, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in CareDx's Xenotransplantation Innovation Day, a virtual event that will feature a leading panel of transplant experts who will share the latest advancements in the field.

Miromatrix to Participate in CareDx's Xenotransplantation Innovation Day

EDEN PRAIRIE, Minn., March 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced the appointment of Jim Douglas as the Company's new Chief Financial Officer (CFO) effective March 1, 2022. As CFO, Jim will lead Miromatrix's finance organization and oversee all financial activities of the corporation. Mr. Douglas will succeed Brian Niebur, who will continue to serve Miromatrix as the Vice President of Finance.

Miromatrix Names Jim Douglas as New Chief Financial Officer

The request puts Miromatrix on the path for Phase I IND submission and an in-human trial in 2H2022 The request puts Miromatrix on the path for Phase I IND submission and an in-human trial in 2H2022

Miromatrix Submits Pre-IND Request to the FDA for Its External Liver Assist Product to Treat Acute Liver Failure

Ross Stores

Miromatrix Medical Inc. (MIRO) CEO Jeff Ross on Q3 2022 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2021 financial results.

Miromatrix Reports Third Quarter 2021 Results

EDEN PRAIRIE, Minn., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the third quarter 2021 after market close on Monday, November 15, 2021. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Miromatrix to Report Third Quarter 2021 Financial Results

Preclinical study of clinically relevant liver transplants advances the decellularization/recellularization approach, representing a key advancement in new therapies for acute and chronic liver failure patients Preclinical study of clinically relevant liver transplants advances the decellularization/recellularization approach, representing a key advancement in new therapies for acute and chronic liver failure patients

Miromatrix Announces the First Successful Transplant of a Bioengineered Whole Organ in a Large Animal

EDEN PRAIRIE, Minn., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will be added to the Russell Microcap® Index, effective after the U.S. market opens today, September 20, 2021.

Miromatrix Medical Added to Russell Microcap® Index

The biotechnology company working to eliminate the organ transplant waitlist outlines expansion of its clinical work, supported by IPO funds and Series C round, led by Baxter, CareDx, and DaVita The biotechnology company working to eliminate the organ transplant waitlist outlines expansion of its clinical work, supported by IPO funds and Series C round, led by Baxter, CareDx, and DaVita

Miromatrix Announces Key Strategic Investors to Advance the Development of Bioengineered Livers and Kidneys

EDEN PRAIRIE, Minn., June 28, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (Nasdaq: MIRO) ("Miromatrix"), a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives, today announced the closing of its initial public offering of 5,520,000 shares of common stock, including the full exercise by the underwriter of its option to purchase 720,000 shares at a price to the public of $9.00 per share. The common stock is listed for trading on The Nasdaq Capital Market under the ticker symbol "MIRO."

Miromatrix Medical Announces Closing of Initial Public Offering

Confluent

Doximity

Monte Rosa Therapeutics

Grove

Bright Health Group

The IPO tidal wave continued Thursday, with a mix of healthcare and technology startups making their trading debut.

News for Miromatrix Medical Inc Stock (MIRO)